



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

26 March 2026  
EMADOC-1700519818-2994500  
Committee for Medicinal Products for Human Use (CHMP)

## Summary of opinion<sup>1</sup> (post authorisation)

---

### Feraccru ferric maltol

On 26 March 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Feraccru. The marketing authorisation holder for this medicinal product is Norgine B.V.

The CHMP adopted a change to the existing indication as follows:<sup>2</sup>

Feraccru is indicated ~~in adults~~ for the treatment of iron deficiency **in adults and adolescents aged 12 years and older.**

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

---

<sup>1</sup> Summary of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

<sup>2</sup> New text in bold, removed text as strikethrough

**Official address** Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

**Address for visits and deliveries** Refer to [www.ema.europa.eu/how-to-find-us](http://www.ema.europa.eu/how-to-find-us)

**Send us a question** Go to [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact) **Telephone** +31 (0)88 781 6000

An agency of the European Union

